-       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - March 2025
    -  175 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - January 2025
    -  175 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - November 2025
    -  383 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                   -       Report 
   - March 2025
    -  150 Pages 
    Global
   
   From       €3455EUR$3,850USD£3,032GBP 
      €4352EUR$4,850USD£3,820GBP 
                  -       Report 
   - June 2025
    -  160 Pages 
    Global
   
   From       €3699EUR$4,123USD£3,247GBP 
      €4352EUR$4,850USD£3,820GBP 
                -       Report 
   - September 2023
    -  110 Pages 
    Global
   
   From       €5339EUR$5,950USD£4,686GBP 
                  -       Report 
   - April 2023
    -  200 Pages 
    United States
   
   From       €2692EUR$3,000USD£2,363GBP 
      €3365EUR$3,750USD£2,953GBP 
                  -       Report 
   - April 2023
    -  394 Pages 
    Global
   
   From       €5384EUR$6,000USD£4,725GBP 
      €6730EUR$7,500USD£5,907GBP 
                -       Report 
   - November 2025
    -  50 Pages 
    Global
   
   From       €2378EUR$2,650USD£2,087GBP 
             
         Lomustine is a chemotherapy drug used to treat brain cancer. It is a nitrosourea, a type of alkylating agent, and works by interfering with the growth of cancer cells. It is used to treat a variety of brain tumors, including glioblastoma, anaplastic astrocytoma, and medulloblastoma. It is also used to treat other types of cancer, such as Hodgkin's lymphoma and non-Hodgkin's lymphoma.
Lomustine is available in both oral and intravenous forms. It is usually given in combination with other    chemotherapy drugs, such as temozolomide or carboplatin. The drug is generally well tolerated, but can cause side effects such as nausea, vomiting, and hair loss.
The market for lomustine is highly competitive, with several companies offering the drug. Some of the major players in the market include Bristol-Myers Squibb, Merck, Pfizer, and Novartis. Other companies, such as Teva Pharmaceuticals and Mylan, also offer generic versions of the drug. Show Less   Read more